| Value | ₹680.0 Cr |
|---|
BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹743.30
- Market cap
- ₹11,699 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 32.2×Sector 47.2×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Other other announcement announcements
All →Nippon Life India Asset Management Other Announcement
Nippon Life India Asset Management Limited's Registrar and Share Transfer Agent, KFin Technologies Limited, is shifting its corporate office. The relocation is effective from December 1, 2026.
KFIN Technologies Other Announcement
KFin Technologies Limited will shift its corporate office to Rajapushpa West Avenue, Kokapet, Hyderabad, effective December 1, 2026. The company's registered office address remains unchanged.
Ginni Filaments Other Announcement
Ginni Filaments Limited submitted a monthly NIL report regarding the special window for re-lodgement of physical share transfers. No requests were received or processed during October 2026.
Sudarshan Colorants India Other Announcement
Sudarshan Colorants India filed its quarterly shareholding pattern for September 2026. Promoter holding stands at 70.26%, unchanged after an internal inter-se share transfer.
Cords Cable Industries Other Announcement
Cords Cable Industries Limited has dispatched communication letters to shareholders regarding the payment and non-payment of the final dividend for FY 2025-26. The dividend is Rs. 1.20 per share.
State Bank of India Other Announcement
State Bank of India submitted a security cover certificate for the quarter ended September 30, 2026. The certificate confirms nil security cover as the listed debt securities are unsecured.